| Trial ID: | L0847 |
| Source ID: | NCT05624840
|
| Associated Drug: |
Nirmatrelvir/Ritonavir
|
| Title: |
Safety and Clinical and Virologic Outcomes in CKD Patients Treated With Nirmatrelvir-ritonavir
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
COVID-19|Chronic Kidney Disease stage4|Chronc Kidney Disease Stage 5
|
| Interventions: |
DRUG: Nirmatrelvir/ritonavir
|
| Outcome Measures: |
Primary: adverse event, Adverse events during or after treatment with nirmatrelvir-ritonavir (starting on or before day 30), serious adverse events and adverse events leading to discontinuation of nirmatrelvir-ritonavir, 30 days | Secondary: RAT, Time to negative rapid antigen test result, 30 days|Rebound, Rebound of positive rapid antigen test or polymerase chain reaction PCR up to day 30, 30 days|WHO Clinical Progression Scale CPS, Time to progression to CPS 5 up to day 30, 30 days|Symptoms, Time to resolution of symptoms, 30 days|Symptomatic rebound, Symptomatic rebound (symptomatic again after resolution of symptom with positive RAT or PCR), 30 days
|
| Sponsor/Collaborators: |
Sponsor: Chinese University of Hong Kong
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
85
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2022-11-07
|
| Completion Date: |
2023-02-01
|
| Results First Posted: |
|
| Last Update Posted: |
2024-02-07
|
| Locations: |
Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, New Territories, SAR, Hong Kong
|
| URL: |
https://clinicaltrials.gov/show/NCT05624840
|
